ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1634

Thrombophilia Associated with DFS70 Antibodies

Julien Marlet1, Jean- Luc Charuel1, Isabelle Martin-Toutain2, Pascale Ghillani-Dalbin1, Zahir Amoura3, Annick Ankri4 and Makoto Miyara1,5, 1Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 2Department of Hematology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 3Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 4Groupe Hospitalier Pitié Salpétrière, service d'hématologie biologique, Paris, France, 5Internal medicine 2, French national reference center for lupus and antiphospholipid syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antinuclear antibodies (ANA) and thrombosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose

The search for antinuclear antibodies (ANA) by indirect immunofluorescence (IIF) on Hep-2 cells is routinely performed as the first step for the biological diagnosis of systemic autoimmune diseases. Anti-DFS70 antibodies are a type of ANA defined by a nuclear dense fine speckled (DFS) IIF pattern, first described in 1994. It has also been reported that anti-DFS70 antibodies were the most frequent type of ANA found in healthy individuals. We therefore conducted a retrospective study on a large number of patients tested positive for anti-DFS70 antibodies

Methods /Patients

The first group of patients, the anti-DFS+ group, included patients selected among those undergoing routine antinuclear antibodies testing (ANAs) at the Pitié-Salpêtrière hospital (Paris, France). Patient inclusion started on the 1st of July 2011 and ended on the 31st of July 2013. The criterion of inclusion was an ANA testing positive with a DFS pattern at titer higher or equal to 1:80. Anti-DFS70 antibodies were confirmed with QUANTA Flash DFS70 immunoassay (Inova diagnostics). 441 patients were included.

The second group of patients, the thrombosis group, included patients consulting in hematology at the Pitié-Salpêtrière hospital (Paris, France) who were screened for the first time for a factor V Leiden mutation, a test performed only in patients with a history of thrombosis. Patient inclusion started on the 1st of January 2013 and ended on the 31st of December 2013. 

Clinical history of all patients was retrospectively analyzed by clinical chart review of medical records

Results

The anti-DFS+ group included 441 patients. The prevalence of SARD among anti-DFS+ patients was low (18%, n=81) consistent with previous reports and the majority of them were followed up in internal medicine departments (82 %). Among them, 51 patients had SLE (11.6 %), 9 RA (2 %), 15 primary Sjogren syndrome (3.4 %) 3 inflammatory myositis (0.7 %) and 2 with mixed connective tissue diseases. Among the other patients, 17 patients had multiple sclerosis (3.9 %) and 16 thyroiditis (3.6 %).

Moreover, we observed an unexpectedly high prevalence of thrombotic events in the anti-DFS+ group (12 %, 54 patients).

We thus constituted a control thrombosis group with patients followed in a single tertiary center for thrombosis. All patients referred (n=67) for the first time to the center for thrombotic events were included. Interestingly, 10.4% of patients in the thrombosis group were positive for anti-DFS antibodies.

Prevalence of arterial thrombosis and venous thrombosis in the whole DFS+ population were respectively of 2.9 %, 6.1 % and prevalence of obstetric syndrome (fetal loss, HELLP or pre-eclampsia) in anti-DFS+ women was 6.3 %. One patient had both arterial and venous thrombosis, another had both arterial thrombosis and obstetric syndrome and four patients had both venous thrombosis and obstetric syndrome.

Conclusion

Presence of DFS70 antibodies on ANA testing may be associated with thrombophilia


Disclosure:

J. Marlet,
None;

J. L. Charuel,
None;

I. Martin-Toutain,
None;

P. Ghillani-Dalbin,
None;

Z. Amoura,
None;

A. Ankri,
None;

M. Miyara,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/thrombophilia-associated-with-dfs70-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.